VM
Therapeutic Areas
Allogene Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Cemacabtagene ansegedleucel (cema-cel) | Frontline Large B-Cell Lymphoma (LBCL) / DLBCL (MRD+ consolidation) | Phase 2 |
| ALLO-316 | CD70+ Advanced or Metastatic Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 |
| ALLO-329 | Autoimmune Disease | Phase 1 |
| ALLO-501/501A | Relapsed/Refractory Non-Hodgkin Lymphoma (r/r NHL) | Phase 1 |